Lamivudine-resistant chronic hepatitis B: An observational study on adefovir in monotherapy or in combination with lamivudine

Journal of Hepatology

Volumn 48, Issue 4, 2008, Pages 540-547

  Gaia, Silvia ^a   Barbon, Valeria ^a   Smedile, Antonina ^a   Olivero, Antonella ^a   Carenzi, Silvia ^a   Lagget, Marco ^a   Alessandria, Carlo ^a   Rizzetto, Mario ^a   Marzano, Alfredo ^a  

^a MOLINETTE HOSPITAL   (Italy)

Author keywords

Adefovir dipivoxil; Chronic hepatitis B; Lamivudine; Resistant mutants

Indexed keywords

ADEFOVIR; LAMIVUDINE;

ARTICLE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; VIROLOGY; VIRUS LOAD;

ADENINE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; PHOSPHONIC ACIDS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 39849111320     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2007.12.018     Document Type: Article

References (41)

1. Mutimer D. Review article: hepatitis B and liver transplantation. Aliment Pharmacol Ther 23 (2006) 1031-1041
2. Liaw Y.F. The current management of HBV drug resistance. J Clin Virol 34 (2005) S143-S146
3. Perrillo R.P. Current treatment of chronic hepatitis B: benefits and limitations. Semin Liver Dis 25 (2005) 20-28
4. Craxi{dotless}̀ A., Antonucci G., and Cammà C. Treatment options in HBV. J Hepatol 44 (2006) S77-S83
5. Tassopoulos N.C., Volpes R., Pastore G., Heathcote J., Buti M., Goldin R.D., et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine precore mutant study group. Hepatology 29 (1999) 889-896
6. Liaw Y.F., Leung N.W., Chang T.T., Guan R., Tai D.I., Ng K.Y., et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 119 (2000) 172-180
7. Gaia S., Marzano A., Smedile A., Barbon V., Abate M.L., Olivero A., et al. Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis. Aliment Pharmacol Ther 20 (2004) 281-287
8. Chang T.T., Lai C.L., Chien R.N., Guan R., Lim S.G., Lee C.M., et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 19 (2004) 1276-1282
9. Di Marco V., Di Stefano R., Ferraro D., Almasio P.L., Bonura G., Giglio M., et al. HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy. Antivir Ther 10 (2005) 431-439
10. Perrillo R., Hann Hw.H., Mutimer D., Willems B., Leung N., Lee W.M., et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterol Jan 126 (2004) 81-90
11. Lampertico P., Viganò M., Manetti E., Iavarone M., Lunghi G., and Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 42 (2005) 1414-1419
12. Marzano A., Lampertico P., Mazzaferro V., Carenzi S., Viganò M., Romito R., et al. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl 11 (2005) 532-538
13. McMahon B.J. Selecting appropriate management strategies for chronic hepatitis B: who to treat. Am J Gastroenterol 101 (2006) S7-S12
14. Keeffe E.B., Dieterich D.T., Han S.H., Jacobson I.M., Martin P., Shoiff R., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 4 (2006) 936-962
15. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis b for up to 5 years. Gastroenterology 131 (2006) 1743-1751
16. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 352 (2005) 2673-2681
17. Peters M.G., Hann Hw H., Martin P., Heathcote E.J., Buggisch P., Rubin R., et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 126 (2004) 91-101
18. Vassiliadis T., Nikolaidis N., Giouleme O., Tziomalos K., Grammatikos N., Patsiaoura K., et al. Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 21 (2005) 531-537
19. Kim K.M., Choi W.B., Lim Y.S., Lee H.C., Chung Y.H., Lee Y.S., et al. Adefovir dipivoxil alone or in combination with ongoing lamivudine in patients with decompensated liver disease and lamivudine-resistant hepatitis B virus. J Korean Med Sci 20 (2005) 821-828
20. Fung S.K., Chae H.B., Fontana R.J., Conjeevaram H., Marrero J., Oberhelman K., et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 44 (2006) 283-290
21. Rapti I., Dimou E., Mitsoula P., and Hadziyannis S.J. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 45 (2007) 307-313
22. Yeon J.E., Yoo W., Hong S.P., Chang Y.J., Yu S.K., Kim J.H., et al. Resistance to adefovir dipivoxil (ADV) in lamivudine-resistant chronic hepatitis B patients treated with ADV. Gut 55 (2006) 1488-1495
23. Yim H.J., Hussain M., Liu Y., Wong S.M., Fung S.K., and Lok A.S. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 44 (2006) 703-712
24. Locarnini S., Qi X., Arterburn S., Snow A., Brosgart C.L., Currie G., et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB) (abstract). J Hepatol 42 (2005) A36
25. Brunelle M.N., Jacquard A.C., Pichoud C., Durantel D., Carrouee- Durantel S., Villenueve J.P., et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 41 (2005) 1391-1398
26. Perrillo R.P. Therapy of hepatitis B - viral suppression or eradication?. Hepatology 43 (2006) S182-S193
27. Liaw Y.W., Lee C.M., Chein R.N., and Yeh C.T. Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis. J Viral Hep 13 (2006) 250-255
28. Mutimer D., Pillav D., Cook P., Ratcliffe D., O'Donnel K., Dowling D., et al. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy. J Infect Dis 181 (2000) 713-716
29. Lee Y.S., Su D.J., Lim Y.S., Jung S.W., Kim K.M., Lee H.C., et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 43 (2006) 1385-1391
30. Osborn M.K., and Lok A.S. Antiviral options for the treatment of chronic hepatitis B. J Antimicrob Chemother 57 (2006) 1030-1034
31. Hadziyannis S.J. New developments in the treatment of chronic hepatitis B. Expert Opin Biol Ther 6 (2006) 913-921
32. Lada O., Benhamou Y., Cahour A., Katlama C., Poynard T., and Thibault V. In vitro susceptibility of lamivudine-resistant hepatitis b virus to adefovir and tenofovir. Antivir Ther 9 (2004) 353-363
33. Suzuki F., Kumada H., and Nakamura H. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy. J Med Virol 78 (2006) 1025-1034
34. Paik Y.H., Han K.H., Hong S.P., Lee W.H., Lee K.S., Kim S.O., et al. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B. Antivir Ther 11 (2006) 447-455
35. Werle B., Cinquin K., Marcellin P., Pol S., Maynard M., Trepo C., et al. Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy. J Viral Hepatol 11 (2004) 74-83
36. Olivero A., Ciancio A.L., Abate M.L., Gaia S., Smedile A., and Rizzetto M. Performance of sequence analysis, INNO-LiPA line probe assays and AFFIGENE assays in the detection of hepatitis B virus polymerase and precore/core promoter mutations. J Viral Hepatol 13 (2006) 355-362
37. Sertoz R.Y., Erensoy S., Pas S., Akarc U.S., Ozgenc F., Yamazhan T., et al. Comparison of sequence analysis and INNO-LiPA HBV DR line probe assay in patients with chronic hepatitis B. J Chemother 17 (2005) 514-520
38. Dusheiko G., and Danta M. Telbivudine for the treatment of chronic hepatitis B. Drugs Today 43 (2007) 293-304
39. Ruiz-Sancho A., Sheldon J., and Soriano V. Telbivudine: a new option for the treatment of chronic hepatitis B. Expert Opin Biol Ther 7 (2007) 751-761
40. Qi X., Xiong S., Yang H., Miller M., and Delaney IV W.E. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 12 (2007) 355-362
41. Lok A.S., Zoulim F., Locarnini S., Bartholomeus A., Ghany M., Pawlotsky J.M., et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 46 (2007) 254-265